Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.135 EUR | +0.33% |
|
-3.74% | +11.05% |
Jan. 31 | Almirall Sells Pain Reliever Drug, Licenses Cough Medicine in Spain | MT |
Jan. 14 | Almirall, S.A. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 05:15 PM |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Commercial Areas - Own Network (Europe) | 540M | 535M | 594M | 659M | 709M | |||||
Total Assets | 561M | 556M | 553M | 561M | 958M | |||||
Income Tax Expense | - | - | - | - | - | |||||
CAPEX | -74.4M | - | -41.44M | -20.42M | - | |||||
EBT | 197M | 201M | - | - | - | |||||
Gross Profit | 377M | - | - | - | - | |||||
D&A | 35.52M | 32.86M | 32.86M | 31.41M | 30.87M | |||||
Operating Income | 197M | 201M | 260M | 263M | 270M | |||||
Net Income | 197M | 201M | 260M | 263M | 270M | |||||
Commercial Areas - Licensees | 111M | 147M | 114M | 86.62M | 88.22M | |||||
Total Assets | 357M | 333M | 314M | 256M | 235M | |||||
Income Tax Expense | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
EBT | 62.82M | 98.44M | - | - | - | |||||
Gross Profit | 78.96M | - | - | - | - | |||||
D&A | 9.12M | 8.4M | 8.4M | 9.77M | 10M | |||||
Operating Income | 63.62M | 98.44M | 65.9M | 27.11M | 29.1M | |||||
Net Income | 62.82M | 98.44M | 65.9M | 27.11M | 29.1M | |||||
Commercial Areas - Own Network (United States) | 179M | 100M | 92.49M | 74.18M | 57.49M | |||||
Total Assets | 677M | 519M | 449M | 390M | 265M | |||||
Interest Expense | -594K | - | - | - | - | |||||
Income Tax Expense | 7.4M | -16.75M | 5.81M | 2.6M | 1.53M | |||||
CAPEX | -14.9M | - | - | -3.15M | - | |||||
EBT | 28.82M | -27.83M | - | - | - | |||||
Gross Profit | 151M | - | - | - | - | |||||
D&A | 52.15M | 51.28M | 51.82M | 48.96M | 41.6M | |||||
Operating Income | 46.61M | -27.83M | -119M | -62.88M | -90.11M | |||||
Net Income | 21.42M | -11.07M | -125M | -65.48M | -91.64M | |||||
Other Areas - Corporate Services and Manufacturing | 79.25M | 31.96M | 36.21M | 59.19M | 44.45M | |||||
Total Assets | 824M | 849M | 772M | 875M | 810M | |||||
Interest Expense | -21.04M | - | - | - | - | |||||
Income Tax Expense | 14.97M | 21.71M | 25.96M | 24.15M | 19.75M | |||||
CAPEX | -25.84M | -42.4M | -31.72M | -75.72M | - | |||||
EBT | -69.82M | -115M | - | - | - | |||||
Gross Profit | -3.35M | - | - | - | - | |||||
D&A | 16.32M | 14.88M | 11.59M | 14.81M | 26.28M | |||||
Operating Income | -47.65M | -102M | -130M | -77.62M | -103M | |||||
Net Income | -84.79M | -136M | -170M | -118M | -134M | |||||
Other Areas - Research and Development Activity | 1.94M | 1.07M | - | - | - | |||||
Total Assets | 28.26M | 33.79M | 54.35M | 65.42M | 108M | |||||
CAPEX | -1.03M | -10.05M | -31.33M | -28.33M | - | |||||
EBT | -90.78M | -77.8M | - | - | - | |||||
Gross Profit | 627K | - | - | - | - | |||||
D&A | 5.79M | 5.22M | 4.71M | 4.89M | 5M | |||||
Operating Income | -90.28M | -77.8M | -71.91M | -103M | -111M | |||||
Net Income | -90.78M | -77.8M | -71.91M | -103M | -111M | |||||
Corporate and Other | - | - | - | - | - | |||||
Income Tax Expense | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
Gross Profit | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Net Income | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
Gross Profit | 58.48M | - | - | - | - | |||||
D&A | 10.52M | 10.45M | 10.55M | 10.8M | 10.57M | |||||
Operating Income | - | - | - | - | - | |||||
Net Income | - | - | - | - | - |
Geographical Revenue Distribution History
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Spain | 243M | 237M | 250M | 274M | 297M | |||||
Germany | - | - | - | 204M | 218M | |||||
Other Countries | - | - | - | 192M | 177M | |||||
Italy | - | - | - | 61.08M | 74.83M | |||||
United States | - | - | - | 74.18M | 57.49M | |||||
France | - | - | - | 35.21M | 42.71M | |||||
United Kingdom | - | - | - | 22.83M | 27.8M | |||||
Unallocated | 26.56M | 26.2M | 27.09M | - | - | |||||
Europe (Excluding Spain) and The Middle East | 357M | 394M | 407M | - | - | |||||
Corporate Management and Revenue Not Allocated to Other Segments | - | - | - | - | - | |||||
America, Asia and Africa | 228M | 150M | 143M | - | - |
- Stock Market
- Equities
- ALM Stock
- Financials Almirall, S.A.
- Business Segments